WO2004096265A1 - Nutriment liquide contenant une hormone de croissance humaine et procede de preparation correspondant - Google Patents

Nutriment liquide contenant une hormone de croissance humaine et procede de preparation correspondant Download PDF

Info

Publication number
WO2004096265A1
WO2004096265A1 PCT/CN2003/000698 CN0300698W WO2004096265A1 WO 2004096265 A1 WO2004096265 A1 WO 2004096265A1 CN 0300698 W CN0300698 W CN 0300698W WO 2004096265 A1 WO2004096265 A1 WO 2004096265A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
heme iron
weishengli
active peptide
minutes
Prior art date
Application number
PCT/CN2003/000698
Other languages
English (en)
Chinese (zh)
Inventor
Shenggang Fan
Longjiang Huo
Ping Ju
Ningbo Feng
Original Assignee
Yantai Apollo Biotechnology, Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yantai Apollo Biotechnology, Co., Ltd. filed Critical Yantai Apollo Biotechnology, Co., Ltd.
Priority to AU2003261569A priority Critical patent/AU2003261569A1/en
Publication of WO2004096265A1 publication Critical patent/WO2004096265A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/315—Zinc compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Definitions

  • the invention relates to the field of biotechnology, in particular to an oral solution capable of delaying or even reversing senescence and enhancing immune function, and a preparation method thereof.
  • the purpose of the present invention is to overcome the shortcomings of the prior art mentioned above and provide a vitality oral solution capable of delaying aging and enhancing immune function. It mainly solves the problems of large amount of existing products, large side effects, high cost, short storage time of active factors, and low utilization of active ingredients.
  • Another object of the present invention is to provide a method for preparing a vitality liquid.
  • the present invention is achieved as follows: Weishengli oral liquid, which is composed of the following components by weight parts, active peptides 0. 15-0. 50, amino acids 50- 100, heme iron 20-80 , Sodium selenite 0.30-0. 80, magnesium lactate 0.18-0. 30, zinc gluconate 0.25-0. 50.
  • a preferred embodiment of the present invention is that the weight ratio of each component is: active peptide 0.18-0. 40, amino acid 55-80, heme iron 30-60, sodium selenite 0. 35-0. 60, magnesium lactate 0. 19-0. 25, zinc gluconate 0. 28-0. 40.
  • a best embodiment of the present invention is that the weight ratio of each component is: active peptide 0.20, amino acid 58, heme iron 35, sodium selenite G. 40, magnesium lactate 0. 20, zinc gluconate 0.30.
  • the method for preparing the Weishengli oral liquid according to the present invention comprises the following process steps:
  • the first step is ozone treatment. Weigh each component and treat it with ozone;
  • the second step is to prepare nano powder. Put amino acid and heme iron into compound high-shear crushing disperser to prepare nano powder;
  • the third step is ultrasonic mixing. Transfer the nano-powder into the ultrasonic mixer, add active peptides after 30 minutes, continue mixing for 60 minutes, and freeze to -18 ° C;
  • the fourth step is mixing. Blend each component at 2 ° C, mix well;
  • the fifth step is packaging. ⁇ Use sterile cans to make finished products.
  • the active peptide HGH of the present invention is an abbreviation of Human Growth Hormone, and is also called human growth hormone. It is a physiologically active substance secreted by the endocrine glands. The body's most important hormone (protein peptide), which is composed of 191 amino acid molecules, is the commander of all other hormones.
  • the Weishengli oral liquid of the present invention is based on the traditional knowledge of traditional Chinese medicine for thousands of years, combined with the achievements of modern pharmacological research and the latest cutting-edge bioengineering technology.
  • Human free radicals have significant functions all the way to thinking and emotion. It can fight diseases, activate the immune system, make people less sick, increase physical strength, Energizing, working long hours without feeling tired. Reveals a person's mental outlook, full of confidence, and high emotions. Revitalizes skin and bones. And it is an effective weight-loss medicine to reshape the body, selectively reduce deep fat in the waist, abdomen and thigh, and increase muscle. Regenerate organs such as liver, lungs, and kidneys, and restore organs and tissues to a younger level.
  • telomeres decreases with cell division. At a certain level, "telomeres" disappear, cells stop dividing, and people will age and die.
  • telomere is controlled by the “telomerase” in the nucleus. Normally, “telomerase” is in the “off” state, and active peptides (such as HGH, IFG-1) enter the cell through the blood, and it acts on the DNA of "telomerase”, activates telomerase, and makes It is in an “open” state and increases the length of telomeres, thereby delaying aging.
  • active peptides such as HGH, IFG-1
  • the Weishengli oral liquid of the present invention can promote the increase of immune factors in the human body (including: Cytokines, interleukins 1 and 2, immunoglobulin G, tumor necrosis factor), thereby enhancing the immune function.
  • the Weishengli oral liquid provided by the invention provides important active peptides of the human body and promotes the secretion of glands, thereby enabling healthy development of human cells, bones, cartilage, muscles, skin, liver and kidneys, and delaying aging. After inspection, it contains a variety of amino acids and trace elements required by the human body, and various indicators are far higher than the standards of health foods, and the detection indicators of their fungi are far lower than the standards of health foods.
  • the Weishengli oral liquid of the present invention has obvious effects after taking it, and the majority of users take deep sleep on the second day after taking it; on the third day, the user's physical strength increases, fatigue is weakened, and his complexion becomes ruddy; one week later, Wet skin, reduced hair loss, increased energy, fast wound healing, reduced local edema, lightened scars, improved vision (presbyopia), reduced fat, increased appetite, improved sexual function, reduced female dryness; after one month, memory significantly increased, Decreased white hair, faded spots, disappeared small facial wrinkles, lightened dark circles, lightened age spots, decreased waist fat, female menopause may resume menstruation, increased immunity, increased endurance, energetic, refractory migraine, high blood pressure The symptoms of vertigo disappeared, and old diseases such as joint pain, rheumatism, and lumbar muscle strain improved significantly; two months, muscle strength increased, fat was further reduced, weight adjustment tended to be normal, fingers, toes Nail growth is improved, sexual function is enhanced, strength is increased, skin is moisturized
  • An effect survey conducted in 2001 included 800 people, including entrepreneurs, senior executives, and most doctors, accounting for 20 °. .
  • the data of 202 subjects were randomly selected for analysis.
  • the 202 people ranged from 36 to 74 years old, and women accounted for 19%.
  • the average treatment time of 202 people was 180 days, with a minimum of 1 month and a maximum of 2 years.
  • results are as follows: 89% of pathological solutions, 84% of increased cardiac contractility, 85% of reduced cholesterol, 81% of increased muscle, 72% of reduced fat, and 81% of improved endurance, 68% increase in skin thickness, 71% increase in skin elasticity, 61% disappearance of wrinkles, 57% increase in wound healing ability, 58% decrease in hot flashes, and 39% regular menstruation. 78% increase confidence in life, 70% skin thinning and whitening, 89% increase in energy, 73% mood stabilization, 70% resistance to common diseases, 60% increase in memory, old 55% of wounds healed, and 36% were new hair.
  • the Weishengli oral liquid according to the present invention has prominent substantive characteristics and significant progress:
  • the physiological activity of the active factor can be kept at room temperature for two years;
  • the present invention adopts the form of oral spray instead of oral administration, it can be directly absorbed from the oral mucosa under the tongue and enter the blood microcirculation, thereby avoiding the active ingredient being largely decomposed and inactivated in the gastrointestinal tract.
  • Example 1 Weigh 0.20g of active peptide, 58g of amino acid, 35g of heme iron, 0.40g of sodium selenite, 0.20g of magnesium lactate, 0.30g of zinc gluconate, and treat with ozone.
  • the amino acid and heme iron were put into a compound high-shear crushing and dispersing machine to prepare nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
  • Example 2 Weigh 0.30 g of active peptide, 80 g of amino acid, 40 g of heme iron, 0.46 g of sodium selenite, 0.18 g of magnesium lactate, and 0.35 g of gluconate, respectively, and treat with ozone.
  • the amino acid and heme hydrazone were put into a compound high-shear crushing disperser to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
  • Example 3 0.18 g of active peptide, 55 g of amino acid, 30 g of heme iron, 0.35 g of sodium selenite, 0.19 g of magnesium lactate, and 0.28 g of zinc gluconate were weighed, respectively, and treated with ozone.
  • the amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed with hooks, and then sterilized canned to prepare the vitality oral solution of the present invention.
  • Example 4 Weigh 0.40 g of active peptide, 80 g of amino acid, 60 g of heme iron, 0.60 g of sodium selenite, 0.25 g of magnesium lactate, and 0.40 g of zinc gluconate, respectively, and treat with ozone.
  • the amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nano powder to the ultrasonic mixer, add active peptide after 30 minutes and continue mixing for 60 minutes Minutes, then frozen to -18 ° C. Formulated according to the distribution ratio of each group at 2 ° C, mixed, and then aseptically canned to prepare the vitality oral solution of the present invention.
  • Example 5 0.15 g of active peptide, 50 g of amino acid, 20 g of heme iron, 0.30 g of sodium selenite, 0.18 g of magnesium lactate, and 0.25 g of zinc gluconate were weighed, respectively, and treated with ozone.
  • the amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.
  • Example 6 0.50 g of active peptide, 100 g of amino acid, 80 g of heme iron, 0.80 g of sodium selenite, 0.30 g of magnesium lactate, and 0.50 g of zinc gluconate were weighed and treated with ozone.
  • the amino acid and heme iron are put into a compound high-shear crushing and dispersing machine to prepare a nano powder. Transfer the nanopowder into the ultrasonic mixer, add the active peptide after 30 minutes and continue mixing for 60 minutes, then freeze to -18 ° C. Formulated at 2 ° C according to the distribution ratio of each group, mixed, and then sterilized canned to prepare the vitality oral solution of the present invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte à un nutriment liquide qui permet de réguler l'immunité et de retarder la sénilité. Il se compose d'une hormone de croissance humaine, d'acides aminés, de fer hémique, de sélénite de sodium, de lactate de magnésium et de gluconate de zinc. Chaque composant de ce nutriment liquide est traité avec de l'ozone et broyé mécaniquement sous forme de poudre nanométrique.
PCT/CN2003/000698 2003-04-30 2003-08-20 Nutriment liquide contenant une hormone de croissance humaine et procede de preparation correspondant WO2004096265A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003261569A AU2003261569A1 (en) 2003-04-30 2003-08-20 Nutrient liquid containing human growth hormone and the preparation method thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN03112375A CN1449819A (zh) 2003-04-30 2003-04-30 维生力口服液及其制备方法
CN03112375.9 2003-04-30

Publications (1)

Publication Number Publication Date
WO2004096265A1 true WO2004096265A1 (fr) 2004-11-11

Family

ID=28684011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2003/000698 WO2004096265A1 (fr) 2003-04-30 2003-08-20 Nutriment liquide contenant une hormone de croissance humaine et procede de preparation correspondant

Country Status (3)

Country Link
CN (1) CN1449819A (fr)
AU (1) AU2003261569A1 (fr)
WO (1) WO2004096265A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932524A1 (fr) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Préparations pharmaceutiques pour le traitement de maladies inflammatoires

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104434A (zh) * 1993-11-13 1995-07-05 西安宝安生物工程有限公司 乳酸全营养素及其生产工艺
CN1368383A (zh) * 2001-02-09 2002-09-11 济南百伦思营养食品有限公司 复方激素保健品的配方及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1104434A (zh) * 1993-11-13 1995-07-05 西安宝安生物工程有限公司 乳酸全营养素及其生产工艺
CN1368383A (zh) * 2001-02-09 2002-09-11 济南百伦思营养食品有限公司 复方激素保健品的配方及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1932524A1 (fr) * 2006-12-13 2008-06-18 Ludwig-Maximilians-Universität München Préparations pharmaceutiques pour le traitement de maladies inflammatoires

Also Published As

Publication number Publication date
AU2003261569A1 (en) 2004-11-23
CN1449819A (zh) 2003-10-22

Similar Documents

Publication Publication Date Title
CA2634953C (fr) Formulations et traitements destines au bien-etre
CN109172491A (zh) 一种具有抗衰老和活血化瘀功能的霜剂及其制备方法
CN111388650A (zh) 平衡雄性荷尔蒙增强男士魅力的组合物及其制备方法
CN109464348A (zh) 一种具有美容和改善亚健康症状的霜剂及其制备方法
JPH05505819A (ja) 尋常性ざ瘡の治療および老化遅延のための組成および方法
Furkatovna EFFECT OF VITAMIN D DICTION ON BONE MINERAL DENSITY IN MENOPAUSA WOMEN
CN101040710A (zh) 一种内服调节女士内分泌兼外用美容养颜的保健营养冲剂
US20060275505A1 (en) Method and composition for increasing the alkalinity of the body
Furkatovna Vitamin D Deficiency in Menopausa Women
CN112237283A (zh) 一种阿胶糕及其制造方法
CN104606347A (zh) 一种治疗肝肾阴虚型绝经后骨质疏松症的中药制剂
CN106937988A (zh) 一种祛斑调经中药组合物及其制备方法
JPH10120579A (ja) 津液改善用皮膚外用剤
US7262170B2 (en) Pharmaceutical composition for reducing vaginal acidity and treatment of vaginitis, and the use thereof
WO2004096265A1 (fr) Nutriment liquide contenant une hormone de croissance humaine et procede de preparation correspondant
CN114224963A (zh) 一种用于增强免疫力缓解体力疲劳的中药制剂及其制备方法
CN106860509A (zh) 筋骨草胶囊的生产工艺
JPH10114665A (ja) 津液改善剤及びそれを含有する経口投与用組成物
CN113117028A (zh) 一种排毒养颜美白的中药组合物及制备方法
JPH10120561A (ja) 津液改善用皮膚外用剤
RU2222316C2 (ru) Лечебно-косметическое средство
WO2005020746A2 (fr) Procede d'embellissement
Handa Ayurveda for Health & Beauty
WO2005079824A1 (fr) Boisson ou médicament contenant des extraits de bambou comme ingrédient principal
CN113679800A (zh) 桑叶黄精补肾膏及其制备方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP